Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 951

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 951
---
 (a) in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a Material Adverse Effect (without giving effect to any
references therein to any Material Adverse Effect or other materiality qualifications) or (b) for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct,
subject to the qualifications as set forth in the preceding clause (a), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update of or modification to the
Company Disclosure Letter made or purported to have been made after the date of this Agreement shall be disregarded).

(b) . The Company shall have performed or complied with in all material respects all agreements and covenants required to be performed or complied with by it under this Agreement at or prior to the Effective Time.

. Parent shall have received the following documents, each of which shall be in full force and effect:

(ii) a certificate pursuant to Treasury Regulations Sections 1.1445-2(c) and 1.897-2(h), together
with a form of notice to the IRS in accordance with the requirements of Treasury Regulations Section 1.897-2(h), in each case, in form and substance reasonably acceptable to Parent;

(iii) Any representation letters and/or other similar factual support letters in connection with the documenting and supporting the Tax
treatment of the Mergers as a “reorganization” within the meaning of Section 368(a) of the Code; and

A-45

(iv) written resignations in forms reasonably satisfactory to Parent, dated as of the
Closing Date and effective as of the Closing executed by the officers and directors of the Company and its Subsidiaries who are not to continue as officers or directors of the Company or such Subsidiaries.

. No Material Adverse Effect will have occurred since the date of this Agreement that is
continuing.

(e) . The Concurrent Investment shall have been completed and the receipt of net proceeds
to Parent of not less than Thirty-Five Million Dollars ($35,000,000), which net proceeds shall have been received by Parent, or will be received by Parent substantially simultaneously with the Closing.

(f) . The Company and (i) each holder of a Company Stock Option granted
under any Company Stock Plan shall enter into an agreement satisfactory to Parent (the “”) and (ii) holders of each of